Paediatric liver transplantation: Indications, timing and medical complications

Journal of Gastroenterology and Hepatology (Australia)

Volumn 14, Issue SUPPL., 1999, Pages

  Cox, Kenneth L ^a   Berquist, William E ^a   Castillo, Ricardo O ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Complications; Immunosuppressive therapy; Paediatric liver transplantation

Indexed keywords

CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; STEROID; TACROLIMUS;

ARTICLE; CHILD; EPSTEIN BARR VIRUS; GRAFT INFECTION; GRAFT REJECTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; PEDIATRIC SURGERY; PRIORITY JOURNAL; SURGICAL MORTALITY; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT INDICATION;

EID: 0032978681     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1999.01904.x     Document Type: Article

References (28)

1. United Network for Organ Sharing (UNOS). Scientific Registry Data for United States 1998.
2. Laurent J, Gauthier F, Hernard O et al. Long-term outcome after surgery for biliary atresia. Study of 40 patients surviving for more than 10 years. Gastroenterology 1990; 99: 1793-7.
3. Kasai M, Mochizuki I, Oukohchi N, Ohi R. Surgical limitation for biliary atresia. Indications for liver transplantation. J. Pediatric Surg. 1989; 24: 851-4.
4. Sveger T, Eriksson S. The liver in adolescents with alpha-I-antitrypsin deficiency. Hepatology 1995; 22: 514-17.
5. Hoffenberg EJ, Narkewicz MR, Sondheimer JM, Smith DJ, Silverman A, Sokol RJ. Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) with onset of cholestasis in infancy. J. Pediatrics 1995; 127: 220-4.
6. McPeake JR, O'Grady JG, Zaman S et al. Liver transplantation for primary hepatocellular carcinoma. Tumor size and number determine outcomes. J. Hepatol. 1993; 18: 226-34.
7. Iwatsuki S, Starzl TE. Role of liver transplantation in the treatment of hepatocellular carcinoma. Semin. Surg. Oncol. 1993; 9: 337-40.
8. Koneru B, Flye MW, Busuttil RW et al. Liver transplantation for hepatoblastoma, The American experience. Ann. Surg. 1991; 213: 118-21.
9. Moyer MS, Balistreri WF. Prolonged neonatal obstructive jaundice. In: Walker WA, Durie PR, Hamilton JR, Walker-Smith JA, Watkins JB, eds. Pediatric Gastrointestinal Disease. Philadelphia: BC Decker Inc.; 1991; 835-48.
10. Bhaduri RR, Mieli-Vergani G. Fulminant hepatic failure: Pediatric aspects. Semin. Liver Dis. 1996; 16: 349-55.
11. Christensen E, Bremmelgaard A, Bahnsen M, Andreasen PB, Tygstrup N. Prediction of fatality in fulminant hepatic failure. Scand. J. Gastroenterol. 1984; 19: 90-6.
12. Devictor D, Desplanques I, Debray D et al. Emergency liver transplantation for fulminant hepatic failure in infants and children. Hepatology 1992; 16: 1156-62.
13. Tan KC, Mondragon RS, Vougas V et al. Liver transplantation for fulminant hepatic failure and late onset hepatic failure in children. Br. J. Surg. 1992; 79: 1192-4.
14. Malatack J, Shaid D, Urbach A et al. Choosing a pediatric recipient for orthotopic liver transplantation. J. Pediatr. 1987; 111: 479-89.
15. Wayman KI, Cox KL, Esquivel CO. Neurodevelopmental outcome of young children with extrahepatic biliary atrcsia 1 year after liver transplantation. J. Pediatr. 1997; 131: 894-8.
16. Cacciarelli T, Esquivel C, Moore D et al. Factors affecting survival after orthotopic liver transplantation in infants. Transplantation 1997; 64: 242-8.
17. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporin for immunosuppression in liver transplantation. N. Engl. J. Med. 1994; 331: 110-15.
18. European FK506 Multicenter Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of allograft rejection. Lancet 1994; 344: 423-8.
19. Cox KL, Freese D. Tacrolimus (FK506): The pros and cons of its use as an immunosuppressant in pediatric liver transplantation. Clin. Invest. Med. 1997; 19: 389-92.
20. Tzakis AG, Reyes J, Todo S et al. FK506 versus cyclosporinc in pediatric liver transplantation. Transplant Proc. 1991; 23: 3010-15.
21. Dunn SP, Falkenstein K, Lawrence JP et al. Monotherapy with cyclosporine for chronic immunosuppression in pediatric liver transplant recipients. Transplantation 1994; 57: 544-7.
22. Melter M, Rodeck B, Kardorff R, Hoyer PF, Brodehl J. Pharmacokinetics of cyclosporine in long-term liver transplant recipients converted from Sandimmun to Neoral. Tranplant. Int. 1997; 10: 419-25.
23. Stegall MD, Wachs ME, Everson G et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: A prospective trial of cyclosporine and tacrolimus. Transplantation 1997; 64: 1755-60.
24. Atkison P, Joubert G, Barron A et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995; 345: 894-6.
25. Cox KL, Laurence-Miyasaki LS, Garcia-Kennedy R et al. An increased incidence of Epstein Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524-9.
26. Cao S, Cox KL. Epstein-Barr virus lymphoproliferative disorders after liver transplantation. Clin. Liver Dis. 1997; 1: 453-69.
27. Nakazato PZ, Burns WB, Moore P, Garcia-Kennedy R, Cox KL, Esqivel CO. Viral prophylaxis in hepatic transplantation; Preliminary report of a randomized trial of acyclovir and gancyclovir. Transplant Proc. 1993; 25: 1935-7.
28. Cao S, Cox KL, Esquivel CO et al. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein Barr virus infection in children following liver transplantation. Transplantation 1998; 66: 851-6.